Vannessa is a first-year DrPH candidate at the Harvard T.H. Chan School of Public Health and is interested in translating epidemiology into policies and strategies that increase global market access to medicines. At Pfizer, she has executed Health Economics and Outcomes Research to increase global reimbursement and access for the smoking cessation drug, Chantix. Vannessa then conducted epidemiological analyses to support Pfizer’s blockbuster pneumococcal conjugate vaccine, Prevnar-13. Previously, she worked as an Emergency Preparedness and Response Planner at the NYC Department of Health & Mental Hygiene and helped develop disaster plans for biological, chemical, and nuclear terrorism, pandemic influenza and other disease outbreaks, and natural disasters such as coastal storms. Born in Nashville, TN but raised in Forsyth, GA, she earned her MPH in Epidemiology from Columbia University with a focus on Infectious Disease Epidemiology. Vannessa holds a B.S. in Neuroscience & Behavioral Biology from Emory University and is a Bill & Melinda Gates Millennium Scholar. Upon completion of her DrPH, she plans to pursue leadership positions in the pharmaceutical industry and develop community heath engagement initiatives to increase knowledge about and access to life-saving treatments in underserved populations. She loves cooking, baking, and horseback riding.